An increased expression was documented in urine of patients with bladder cancer, prostate cancer, pancreatic cancer, colorectal cancer, breast cancer, lung cancer and solid sarcomas and proposed as a new theranostic marker [64,66,67,68] According to the results of multivariate regression analysis (Table 3), its plasma and urinary level were documented in significant interrelation with Hb level in BEN patients. The gene discussed is GSTM1; the disease is breast carcinoma.